María Jesús Muñoz-Yánez

María Jesús Muñoz-Yánez

Auto-generated profile, based on publicly available information

María Jesús Muñoz-Yánez

Universidad Gabriela Mistral, Av. Andrés Bello 1337, Santiago 7500533, Chile

Research Focus & Metrics

Academic Career Length

3Years (2024-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
9 October 2024 in Biomedicines
Verified
Journal Article
Open access
ALAndrea Lizama-Lefno
Andrea Lizama-Lefno
KPKrystel mojica Poveda
Krystel mojica Poveda
ARangel Roco
angel Roco
JVJuan Ignacio Vargas
Juan Ignacio Vargas
NDNelia González Droguett
Nelia González Droguett
SFSergio Flores-Carrasco
Sergio Flores-Carrasco
Background/Objectives: Fibromyalgia (FM) is a chronic syndrome characterized by widespread musculoskeletal pain, fatigue, sleep disturbances, and mental health issues. It affects approximately 1.78% of the general population; an estimated 4:1 ratio between women and men is observed. It significantly impacts quality of life and carries both clinical and social stigma. This study aims to evaluate the relationship between drug use and mental health in female patients with fibromyalgia. Methods: This study is prospective, observational, and cross-sectional. A questionnaire was administered to 544 subjects, achieving a representative sample size from a population of 800,000 subjects by using an algorithm for proportion estimation with a known sampling frame. The selection was non-random, making the sampling non-probabilistic. Logistic regression models were applied to assess the effect of drug use on perception of mental health; presence of symptoms such as comprehension and memory problems, insomnia, depression, and anxiety; and severity of cognitive symptoms and non-restorative sleep. To quantify the impact, odds ratios and confidence intervals have been observed. Results: The findings indicate the non-recommended use of medications and reveal the ineffectiveness and adverse effects of drug interactions on mental health. The use of benzodiazepines and sedative-hypnotics is significantly associated with a negative perception of mental health. Benzodiazepines do not improve symptoms or significantly reduce their severity. SSRI antidepressants do not enhance mental health perception; however, when used exclusively, they are effective in reducing the severity, but not the prevalence, of cognitive symptoms. Conclusions: The results highlight the complexity of pharmacological management in FM and raise concerns about the inappropriate use of ineffective or counterproductive drug interactions affecting patients’ mental health. They underscore the need for multidisciplinary and personalized strategies that include close and careful monitoring, as well as the simultaneous use of non-pharmacological treatments that have demonstrated evidence in improving quality of life without negatively affecting mental health, such as patient education, psychological therapy, physiotherapy, and mindfulness.

19 July 2024 in Salud, Ciencia y Tecnología
Verified
Journal Article
Open access
PDF file
EAErick Atenas-Núñez
Erick Atenas-Núñez
M-María Jesús Muñoz -Yánez
María Jesús Muñoz -Yánez
ALAndrea Lizama-Lefno
Andrea Lizama-Lefno
ARangel Roco
angel Roco
MCMarcela Caviedes-Olmos
Marcela Caviedes-Olmos
Introduction: the COVID-19 pandemic generated a significant increase in anxiety and fear in the population, especially in those with chronic conditions such as fibromyalgia. Although there is no evidence that fibromyalgia is a predictor of hospitalization or mortality associated with COVID-19, the infection can worsen fibromyalgia symptoms.Methods: this study focused on evaluating the ability of psychosocial pain factors, such as pain intensity, pain catastrophizing, impact of fibromyalgia, and kinesiophobia, to predict fear of COVID-19 in women with fibromyalgia. A quantitative, observational-analytical design was used, with a sample of 33 women diagnosed with fibromyalgia. Fear of COVID-19 was assessed through a questionnaire and scales were used to measure the predictor variables.Results: it was found that pain catastrophizing was the most significant predictor variable of fear of COVID-19. The correlation between pain catastrophizing and fear of COVID-19 was moderate, and the multiple regression model that included this variable predicted fear of COVID-19 with an adjusted R2 of 0.248.Conclusions: fear of COVID-19 in women with fibromyalgia is related to pain catastrophizing. This study suggests that pain catastrophizing may be an important factor as a predictor of fear in new studies associated with new outbreaks of this disease